MADRAC Bulletin

New Publication: Bulletin MADRAC - April 2016

Written by Jauze · 4 October 2016

Bulletin MADRAC

Welcoming the new MADRAC members (2016-2018)
Pharmacogenomics in Determining Drug Response
Azithromycin: Risk of QT Prolongation and DRESS
Mycophenolate: Important New Information on the Teratogenic Risk
Prolia® and Xgeva® (denosumab): Clinically Significant Cases of Hypercalcaemia after Cessation of Treatment with Denosumab in Paediatric Patients
Viekirax® and Exviera®: Not Recommended in Patients with Moderate Hepatic Impairment (Child-Pugh B)
Xalkori® (crizotinib): Inclusion of a New Warning Regarding Cardiac Failure
Pharmacists: CPD Points for Quality ADR Reports

Not yet rated